西妥昔单抗联合化疗治疗结直肠癌的疗效分析

Analysis of efficacy of first-line treatment with cetuximab combined with chemotherapy in treatment of K-Ras mild-type metastatic colorectal cancer

目的:探讨西妥昔单抗联合不同化疗一线治疗K-Ras野生型转移性结直肠癌(m CRC)的效果及安全性。方法:选取58例K-Ras野生型m CRC患者,随机分为观察组和对照组,每组29例。对照组采用单纯化疗治疗,观察组采用西妥昔单抗联合化疗治疗,两组均完成8周期治疗。比较两组客观缓解率(ORR)、疾病控制率(DCR),观察两组中位无进展生存期(PFS)、中位总生存期(OS),比较两组皮疹发生率。结果:两组ORR差异无统计学意义(P>0.05),观察组DCR显著高于对照组(P<0.05),观察组中位PFS和中位OS显著长于对照组(P<0.05),观察组皮疹发生率显著高于对照组(P<0.05)。结论:西妥昔单抗联合化疗一线治疗K-Ras野生型m CRC较单纯化疗方案能够显著提高近期疗效,延长患者中位PFS和OS,不良反应以皮疹为主。

Objective： To explore the efficacy and safety of first-line treatment with cetuximab combined with different chemotherapy in the treatment of K-Ras mild-type metastatic colorectal cancer（ m CRC）. Methods： A total of 58 patients with K-Ras mildtype m CRC were randomly divided into observation group and control group,29 cases for each group. Control group was treated with single chemotherapy while observation group with cetuximab combined with chemotherapeutic protocol. Both groups finished the 8-cycle treatment. Objective response rate（ ORR） and disease control rate（ DCR） were compared between two groups,median progression-free survival time（ PFS） and median overall survival（ OS） were compared in both groups,and the rate of rash was compared. Results：There was no significant difference between two groups in ORR（ P〈0. 05）,but observation group was markedly higher in DCR than control group（ P〈0. 05）. Meanwhile,observation group was notably loner in median PFS and median OS（ P〈0. 05）,and prominently higher in the rate of rash than control group（ P〈0. 05）. Conclusion： First-line treatment with cetuximab combined with chemotherapeutic protocol can significantly increase the short-term efficacy,and prolong the median PFS and OS of patients with K-Ras mild-type m CRC,and the adverse reactions mainly focus on rash.